Drugs / Elarekibep
Elarekibep
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05794672 | Apr → Jul 2023 | — | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT03921268 | Mar → Jun 2019 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03384290 | Dec 2017 → Oct 2018 | — | Pieris Australia Pty Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04643158 | Mar 2021 → Jul 2023 | asthma | AstraZeneca | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03574805 Comparator | Jun 2018 → Sep 2020 | asthma | Pieris Australia Pty Ltd | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elarekibep | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05794672 ↗ |
| Known as | AZD1402 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04643158 ↗ |
| Known as | PRS-060 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03574805 ↗ |
| Action | Inhibit | “AZD1402 is an inhaled IL-4Rα antagonist” NCT03921268 ↗ |
| Modality | Protein / enzyme biologic | “belongs to a new class of therapeutics, Anticalin® proteins, which are modified lipocalins” NCT03921268 ↗ |
| Route | Inhaled | “administered by oral inhalation or IV infusion” NCT03384290 ↗ |
| Route | Intravenous | “administered by oral inhalation or IV infusion” NCT03384290 ↗ |